Experimental Alzheimer’s drug may slow disease progression, but there are risks: experts
The experimental drug lecanemab showed a 27% slowing of the progression of cognitive decline in patients with early-stage Alzheimer’s disease, according to a study published this week in the New England Journal of Medicine. “These results show that lecanemab shows promise for people with early-stage Alzheimer’s disease, with a significant slowing of decline and a …
Experimental Alzheimer’s drug may slow disease progression, but there are risks: experts Read More »
